1 / 77

ARRHYTHMIAS

ARRHYTHMIAS. TACHYCARDIA >100/min BRADYCARDIA <50/min CARDIAC ARREST Electrical activity Chaotic VF Absent asystole. Action potential. 0. -60. Propagating action potential. 0. -60. Propagating action potential. 0. -60. Propagating action potential. 0. -60.

udell
Download Presentation

ARRHYTHMIAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARRHYTHMIAS • TACHYCARDIA >100/min • BRADYCARDIA <50/min • CARDIAC ARREST Electrical activity • Chaotic VF • Absent asystole

  2. Action potential 0 -60

  3. Propagating action potential 0 -60

  4. Propagating action potential 0 -60

  5. Propagating action potential 0 -60

  6. Propagating action potential 0 -60

  7. Propagating action potential

  8. TREATMENT STRATEGY • PROLONG ACTION POTENTIAL • MODIFY CONDUCTION • STABILISE AUTOMATICITY • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  9. DEPOL Inward  REPOL outward

  10. Propagating action potential

  11. TREATMENT STRATEGY • PROLONG ACTION POTENTIAL • MODIFY CONDUCTION • STABILISE AUTOMATICITY • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  12. DEPOL Inward  REPOL outward

  13. DEPOL Inward  REPOL outward

  14. AUTOMATICITY Physiological: Sinus node Pathological: Reduction/depolarisation of resting membrane potential (e.g. Ischaemia)

  15. TREATMENT STRATEGY • PROLONG ACTION POTENTIAL • MODIFY CONDUCTION • STABILISE AUTOMATICITY • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  16. Tachyarrhythmias • Antiarrhythmic drugs • Vaughan-Williams Classification • Drugs divided according to EP effects on cells • All are negatively inotropic • Can also be pro-arrhythmic

  17. Tachyarrhythmias • Class I • Impede Na transport across cell membrane • Ia increase AP duration eg quinidine, disopyramide, procainamide • Ib shorten AP duration eg lignocaine, mexilitene, propafenone • Ic little effect on AP eg flecainide

  18. Tachyarrhythmias • Class II • Interfere with effects of SNS on the heart eg beta blockers • Class III • Prolong AP duration but do not effect initial Na dependent phase eg sotalol, amiodarone • Class IV • Antagonise Ca transport across cell membrane • SA and AV node particularly susceptible eg verapamil, diltiazem

  19. TREATMENT STRATEGY • PROLONG ACTION POTENTIAL • MODIFY CONDUCTION • STABILISE AUTOMATICITY • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  20. AV Nodal block • [Class II • Interfere with effects of SNS on the heart eg beta blockers] • Class III • Prolong AP duration but do not effect initial Na dependent phase eg sotalol, amiodarone • Class IV • Antagonise Ca transport across cell membrane • SA and AV node particularly susceptible eg verapamil, diltiazem • Adenosine • Specific AV nodal block

  21. EP study: standard fixed wires

  22. EP study: standard fixed wires

  23. RADIOFREQUENCY ABLATION

  24. TREATMENT STRATEGY • STABILISE AUTOMATICITY • PROLONG ACTION POTENTIAL • SLOW CONDUCTION • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  25. RFA: success rates • AVJ 98% • AVNRT 97% • AP 93% (L 95%, R 89%) • AFl 95% • Infarct VT 60-90%, long term 50% • Idiopathic VT 90% • Focal AF 60%

  26. RFA: treatment of choice • AVJ 98% • AVNRT 97% • AP 93% (L 95%, R 89%) • AFl 95% • Idiopathic VT 90% ______________________________ • Infarct VT 60-90%, long term 50% • Focal AF 60%

  27. Atrial flutter

  28. Atrial Flutter: RFA vs AA drugsJACC2000;35:1898 prospective, randomised – 61 pts • SR at 21 months: 36%AAD vs 80% RFA • Rehospitalised: 63% AAD vs 22% RFA • AF: 53% AAD vs 29% RFA • QOL: no change AAD improvement RFA

  29. TREATMENT STRATEGY • PROLONG ACTION POTENTIAL • MODIFY CONDUCTION • STABILISE AUTOMATICITY • INTERRUPT REENTRY • PHARMACOLOGICAL • PHYSICAL • ELECTRICAL STIMULATION • ATP/SHOCK TACHY • PACE BRADY

  30. Concepts of AF: 1900-2000 MULTIPLE WAVELETS Ines, Garrey MOTHER WAVE Lewis HYPEREXCITABILITY Engelmann, Winterberg

  31. WPW syndrome

More Related